Bioline Rx Ltd ADR

BLRXNASDAQ · USD
1.30USD0.00 (-3.71%)
122

Bioline Rx Ltd ADR (BLRX) Covered Calls

Bioline Rx Ltd ADR trades in the Biotechnology industry with an IV Rank of 2.38%, low versus the past year. BLRX's highest covered call setup is the $5.00 strike expiring May 21, 2027, sorted by theoretical annualized return. It's 216.46% out of the money with 193 days to expiration, a 219.62% return until expiration, and a 415.34% theoretical annualized return. Across the setups shown, annualized returns run from 140.04% to 415.34% at strikes between $2.50 and $5.00, with 193 to 193 days to expiration, as of Nov 9, 2026.

Read more

Running BLRX covered calls helps you generate income from Bioline Rx Ltd ADR shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best BLRX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If BLRX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling BLRX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given BLRX covered call is worth writing.

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.

2027-05-211935.00216.460.055.00347.00219.62415.34-3.16+1.0004.95
2027-05-211932.5058.230.255.00117.0074.05140.04-15.82+1.0004.75

As of Nov 9, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank2.38% Low
  • Market cap (M$)6
  • 52 weeks high-67.09%
  • 52 weeks low-3.70%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$22.00
    1592.31% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-23
  • P/E—
  • Future P/E—
  • EPS (ttm)-1.82
  • EPS growth next 5 years—

As of Nov 13, 2026